{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:38:22Z","timestamp":1790289502905,"version":"4.1.0"},"reference-count":79,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","award":["EXCELLENCE\/0918\/0358"],"award-info":[{"award-number":["EXCELLENCE\/0918\/0358"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"EU\u2019s HORIZON 2020 Research and Innovation Program","award":["857122"],"award-info":[{"award-number":["857122"]}]},{"DOI":"10.13039\/100012996","name":"University of Cyprus","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012996","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/02qjrjx09","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) have emerged as promising non-invasive biomarkers for the immunotherapy response in advanced non-small cell lung cancer (NSCLC). However, their clinical utility remains uncertain due to variability in findings across studies. We conducted a systematic review and meta-analysis of studies from 2014 to 2024, assessing the predictive value of ctDNA and CTCs in advanced NSCLC patients receiving immunotherapy. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Forty-four studies were included (28 ctDNA, 16 CTC cohorts). High baseline ctDNA was associated with worse OS (pooled HR = 1.38, 95% CIs: 1.17\u20131.63), while baseline CTC detection predicted worse PFS (pooled HR of 3.65 (95% CIs: 1.58\u20138.41) and OS (pooled HR = 2.30, 95% CIs: 1.54\u20133.44). An on-treatment ctDNA decrease or clearance was associated with improved PFS (pooled HR = 0.34, 95% CIs: 0.25\u20130.47) and OS (pooled HR = 0.33, 95% CIs: 0.24\u20130.44). Evidence for other ctDNA- and CTC-derived biomarkers (blood tumour mutational burden, genomic alterations, dynamic CTC changes, and CTC PD-L1 expression) was limited or inconsistent. The interpretation of these findings is limited by heterogeneity in assay platforms, biomarker definitions, the analytical threshold, and sampling timepoints across studies. While ctDNA and CTCs show significant potential as predictive biomarkers in advanced NSCLC, further validation is needed in larger prospective studies using standardized assays. At present, ctDNA and CTC monitoring can complement but cannot replace radiological assessments in guiding immunotherapy decisions for NSCLC patients.<\/jats:p>","DOI":"10.3390\/ijms27125518","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:37:42Z","timestamp":1781879862000},"page":"5518","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Predictive Role of ctDNA and CTCs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2982-679X","authenticated-orcid":false,"given":"Andrea C.","family":"Kakouri","sequence":"first","affiliation":[{"name":"biobank.cy Center of Excellence in Biobanking and Biomedical Research, University of Cyprus, Nicosia 2029, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-2048","authenticated-orcid":false,"given":"Maria","family":"Spiliotaki","sequence":"additional","affiliation":[{"name":"biobank.cy Center of Excellence in Biobanking and Biomedical Research, University of Cyprus, Nicosia 2029, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5549-9169","authenticated-orcid":false,"given":"Constantinos","family":"Deltas","sequence":"additional","affiliation":[{"name":"biobank.cy Center of Excellence in Biobanking and Biomedical Research, University of Cyprus, Nicosia 2029, Cyprus"},{"name":"University of Nicosia Medical School, Nicosia 2408, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2440-9789","authenticated-orcid":false,"given":"Gregory","family":"Papagregoriou","sequence":"additional","affiliation":[{"name":"biobank.cy Center of Excellence in Biobanking and Biomedical Research, University of Cyprus, Nicosia 2029, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-1936","authenticated-orcid":false,"given":"Haris","family":"Charalambous","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Bank of Cyprus Oncology Centre, Acropoleos Ave 32, Nicosia 2006, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","article-title":"Non-small-cell lung cancer","volume":"1","author":"Gridelli","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non\u2013Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer","volume":"28","author":"Jee","year":"2022","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-024-00985-w","article-title":"Circulating tumour DNA in early stage and locally advanced NSCLC: Ready for clinical implementation?","volume":"22","author":"Normanno","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2300535","DOI":"10.1200\/PO.23.00535","article-title":"Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment","volume":"8","author":"Russo","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"24677","DOI":"10.18632\/oncotarget.8250","article-title":"Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer","volume":"7","author":"Hyun","year":"2016","journal-title":"Oncotarget"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41571-023-00781-y","article-title":"Circulating tumour cells for early detection of clinically relevant cancer","volume":"20","author":"Lawrence","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1038\/srep06269","article-title":"Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: A systematic review and meta-analysis","volume":"4","author":"Luo","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e21965","DOI":"10.1097\/MD.0000000000021965","article-title":"Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review","volume":"99","author":"Zhou","year":"2020","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"13379","DOI":"10.1038\/s41598-018-30780-4","article-title":"The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: A systematic review and meta-analysis","volume":"8","author":"Passiglia","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Shen, H., Jin, Y., Zhao, H., Wu, M., Zhang, K., Wei, Z., Wang, X., Wang, Z., Li, Y., and Yang, F. (2022). Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer. BMC Med., 20.","DOI":"10.1186\/s12916-022-02681-x"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhong, R., Gao, R., Fu, W., Li, C., Huo, Z., Gao, Y., Lu, Y., Li, F., Ge, F., and Tu, H. (2023). Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: A meta-analysis. BMC Med., 21.","DOI":"10.1186\/s12916-023-02849-z"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wang, H., Zhou, F., Qiao, M., Li, X., Zhao, C., Cheng, L., Chen, X., and Zhou, C. (2021). The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.671874"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33922","DOI":"10.18632\/oncotarget.15412","article-title":"Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: A systematic review and meta-analysis","volume":"8","author":"Fan","year":"2017","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e005854","DOI":"10.1136\/jitc-2022-005854","article-title":"Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: A systematic review","volume":"11","author":"Wilson","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102948","DOI":"10.1016\/j.critrevonc.2020.102948","article-title":"Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)","volume":"153","author":"Mildner","year":"2020","journal-title":"Crit. Rev. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"300060521994926","DOI":"10.1177\/0300060521994926","article-title":"Role of circulating tumor cells in diagnosis of lung cancer: A systematic review and meta-analysis","volume":"49","author":"Zhao","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wankhede, D., Grover, S., and Hofman, P. (2022). Circulating Tumor Cells as a Predictive Biomarker in Resectable Lung Cancer: A Systematic Review and Meta-Analysis. Cancers, 14.","DOI":"10.3390\/cancers14246112"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jiang, S.-S., Deng, B., Feng, Y.-G., Qian, K., Tan, Q.-Y., and Wang, R.-W. (2019). Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: A meta-analysis and system review. BMC Pulm. Med., 19.","DOI":"10.1186\/s12890-019-1029-x"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"220151","DOI":"10.1183\/16000617.0151-2022","article-title":"Circulating tumour cells in patients with lung cancer universally indicate poor prognosis","volume":"31","author":"Jin","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2019.04.019","article-title":"EPAC-lung: Pooled analysis of circulating tumour cells in advanced non-small cell lung cancer","volume":"117","author":"Lindsay","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Huang, J., Wang, K., Xu, J., Huang, J., and Zhang, T. (2013). Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: A meta-analysis. PLoS ONE, 8, Erratum in PLoS ONE 2014, 9. https:\/\/doi.org\/10.1371\/annotation\/6633ed7f-a10c-4f6d-9d1d-9c1245822eb7.","DOI":"10.1371\/annotation\/6633ed7f-a10c-4f6d-9d1d-9c1245822eb7"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Altman, D.G., McShane, L.M., Sauerbrei, W., and Taube, S.E. (2012). Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and elaboration. PLoS Med., 9.","DOI":"10.1371\/journal.pmed.1001216"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/annonc\/mdu145","article-title":"Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer","volume":"25","author":"Kerr","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: Phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","article-title":"Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer","volume":"79","author":"Anagnostou","year":"2019","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2767-9764.CRC-22-0258","article-title":"Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non-small Cell Lung Cancer","volume":"2","author":"Frank","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","article-title":"Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e004952","DOI":"10.1136\/jitc-2022-004952","article-title":"Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: Biomarker analysis from a single-arm, phase 2 trial","volume":"10","author":"Han","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/1878-0261.13330","article-title":"Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: Safety, clinical activity and ctDNA responses\u2014The ComIT-1 trial","volume":"17","author":"Horndalsveen","year":"2023","journal-title":"Mol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejca.2017.09.004","article-title":"Very early response of circulating tumour\u2013derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non\u2013small cell lung cancer","volume":"86","author":"Iijima","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1903410","DOI":"10.1002\/advs.201903410","article-title":"Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-Small Cell Lung Cancer","volume":"7","author":"Jia","year":"2020","journal-title":"Adv. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e000527","DOI":"10.1136\/jitc-2020-000527","article-title":"Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression","volume":"8","author":"Leprieur","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1424675","DOI":"10.1080\/2162402X.2018.1424675","article-title":"Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer","volume":"7","author":"Leprieur","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7669","DOI":"10.1002\/cam4.2632","article-title":"Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","article-title":"Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition","volume":"183","author":"Nabet","year":"2020","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1158\/1078-0432.CCR-23-1578","article-title":"Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer","volume":"29","author":"Pellini","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","article-title":"Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab","volume":"24","author":"Raja","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial","volume":"17","author":"Ren","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e001504","DOI":"10.1136\/jitc-2020-001504","article-title":"Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)","volume":"9","author":"Ricciuti","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"971","DOI":"10.21037\/tlcr-22-818","article-title":"Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer","volume":"12","author":"Stensgaard","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/PO.20.00321","article-title":"Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy","volume":"5","author":"Thompson","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/1878-0261.13090","article-title":"Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors","volume":"15","author":"Hiddinga","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11795549221075326","DOI":"10.1177\/11795549221075326","article-title":"Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing","volume":"16","author":"Wang","year":"2022","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1200\/PO.21.00182","article-title":"Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non\u2013Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors","volume":"5","author":"Weber","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/s41467-024-45769-z","article-title":"Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: A phase 2 clinical trial","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/PO.21.00057","article-title":"ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy","volume":"5","author":"Zou","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/1878-0261.13409","article-title":"Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC","volume":"17","author":"Carbonell","year":"2023","journal-title":"Mol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2019.09.005","article-title":"Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer","volume":"137","author":"Guibert","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.21037\/jtd-23-379","article-title":"Clinical value of peripheral blood circulating tumor DNA in predicting the efficacy of immunotherapy for non-small cell lung cancer","volume":"15","author":"Wang","year":"2023","journal-title":"J. Thorac. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14317","DOI":"10.1002\/cam4.6108","article-title":"Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer","volume":"12","author":"Cheng","year":"2023","journal-title":"Cancer Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/1878-0261.13317","article-title":"Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab","volume":"17","author":"Spiliotaki","year":"2023","journal-title":"Mol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e2200457","DOI":"10.1200\/PO.22.00457","article-title":"Monitoring PD-L1 Expression on Circulating Tumor\u2013Associated Cells in Recurrent Metastatic Non\u2013Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy","volume":"6","author":"Moran","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Song, L., Zeng, L., Xiong, Y., Liu, L., Zhou, C., Yang, H., Wang, Z., Xia, Q., and Jiang, W. (2022). Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: A phase II efficacy and biomarker study. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10045-0"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.21037\/tlcr-21-100","article-title":"Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer","volume":"10","author":"Park","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ikeda, M., Koh, Y., Teraoka, S., Sato, K., Oyanagi, J., Hayata, A., Tokudome, N., Akamatsu, H., Ozawa, Y., and Endo, K. (2021). Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers, 13.","DOI":"10.3390\/cancers13102290"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Dall\u2019OLio, F.G., Gelsomino, F., Conci, N., Marcolin, L., De Giglio, A., Grilli, G., Sperandi, F., Fontana, F., Terracciano, M., and Fragomeno, B. (2021). PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non\u2013small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Clin. Lung Cancer, 22.","DOI":"10.1016\/j.cllc.2021.03.005"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cryobiol.2021.07.007","article-title":"The clinical efficacy of argon-helium knife cryoablation combined with nivolumab in the treatment of advanced non-small cell lung cancer","volume":"102","author":"Feng","year":"2021","journal-title":"Cryobiology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1002\/1878-0261.13094","article-title":"Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab","volume":"15","author":"Anido","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Papadaki, M.A., Sotiriou, A.I., Vasilopoulou, C., Filika, M., Aggouraki, D., Tsoulfas, P.G., Apostolopoulou, C.A., Rounis, K., Mavroudis, D., and Agelaki, S. (2020). Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy. Cancers, 12.","DOI":"10.3390\/cancers12061556"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Alama, A., Coco, S., Genova, C., Rossi, G., Fontana, V., Tagliamento, M., Bello, M.G.D., Rosa, A., Boccardo, S., and Rijavec, E. (2019). Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. J. Clin. Med., 8.","DOI":"10.3390\/jcm8071011"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s40425-019-0649-2","article-title":"Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors","volume":"7","author":"Tamminga","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.canlet.2019.10.041","article-title":"PD-L1(+) aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients","volume":"469","author":"Zhang","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Janning, M., Kobus, F., Babayan, A., Wikman, H., Velthaus, J.-L., Bergmann, S., Schatz, S., Falk, M., Berger, L.-A., and B\u00f6ttcher, L.-M. (2019). Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1\/PD-L1 Inhibitors. Cancers, 11.","DOI":"10.3390\/cancers11060835"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41598-018-19245-w","article-title":"Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer","volume":"8","author":"Dhar","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2018.04.001","article-title":"PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab","volume":"120","author":"Guibert","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"31726","DOI":"10.1038\/srep31726","article-title":"Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab","volume":"6","author":"Nicolazzo","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s41588-023-01446-3","article-title":"Single-molecule genome-wide mutation profiles of cell-free DNA for non-invasive detection of cancer","volume":"55","author":"Bruhm","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"eadj9283","DOI":"10.1126\/scitranslmed.adj9283","article-title":"Genome-wide repeat landscapes in cancer and cell-free DNA","volume":"16","author":"Annapragada","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/2159-8290.CD-24-0519","article-title":"Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection","volume":"14","author":"Mazzone","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"217325","DOI":"10.1016\/j.canlet.2024.217325","article-title":"Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profiling","volume":"609","author":"Gerratana","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.21037\/tlcr-2024-1095","article-title":"Monitoring pembrolizumab response in patients with metastatic non-small cell lung cancer using circulating tumour DNA and circulating tumour cells","volume":"14","author":"Kakouri","year":"2025","journal-title":"Transl. Lung Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5518\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:20:30Z","timestamp":1782534030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":79,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27125518"],"URL":"https:\/\/doi.org\/10.3390\/ijms27125518","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]}}}